Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease

被引:38
|
作者
Bucolo, Claudio [1 ,2 ]
Fidilio, Annamaria [1 ]
Fresta, Claudia Giuseppina [1 ]
Lazzara, Francesca [1 ]
Platania, Chiara Bianca Maria [1 ]
Cantarella, Giuseppina [1 ]
Di Benedetto, Giulia [1 ]
Burgaletto, Chiara [1 ]
Bernardini, Renato [1 ]
Piazza, Cateno [3 ]
Barabino, Stefano [4 ]
Drago, Filippo [1 ,2 ]
机构
[1] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Catania, Italy
[2] Univ Catania, Ctr Res Ocular Pharmacol CERFO, Catania, Italy
[3] Univ Catania Consortium Unifarm, Analyt Dept, Catania, Italy
[4] Univ Milan, Ocular Surface & Dry Eye Ctr, Osped L Sacco, Milan, Italy
来源
FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷
关键词
dry eye disease; inflammation; cornea; hydrocortisone; Sjogren syndrome; NF-KAPPA-B; TEAR FILM; TRAIL; CORTICOSTEROIDS; PROLIFERATION; MODELS; ROLES; TESTS; CELLS;
D O I
10.3389/fphar.2019.01240
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To investigate the ocular pharmacological profile of hydrocortisone (HC) using in vitro and in vivo models of dry eye disease. Rabbit corneal epithelial cells (SIRCs) were used to assess the effect of HC in two paradigms of corneal damage: hyperosmotic stress and scratch-wound assay. Dry eye was induced in albino rabbits by topical administration of atropine sulfate or by injection of concanavalin A (ConA) into the lacrimal gland. TNF alpha, TNF-related apoptosis-inducing ligand (TRAIL), IL-1 beta, and IL-8 were determined by ELISA or western blot in a corneal damage hyperosmotic in vitro model, with or without HC treatment. Inflammatory biomarkers, such as TNF alpha, IL-8, and MMP-9, were evaluated in tears of rabbit eye injected with ConA and treated with HC. Tear volume and tear film integrity, in both in vivo models, were evaluated by the Schirmer test and tear break-up time (TBUT). Ocular distribution of four formulations containing HC (0.001%, 0.003%, 0.005%, and 0.33%) was performed in the rabbit eye. Aqueous humor samples were collected after 15, 30, 60, and 90 min from instillation and then detected by LC-MS/MS. Hyperosmotic insult significantly activated protein expression of inflammatory biomarkers, which were significantly modulated by HC treatment. HC significantly enhanced the re-epithelialization of scratched SIRCs. Treatment with HC eye drops significantly reduced the tear concentrations of TNF-alpha, IL-8, and MMP-9 vs. vehicle in the ConA dry eye model. Moreover, HC significantly restored the tear volume and tear film integrity to levels of the control eyes, both in ConA- and atropine-induced dry eye paradigms. Finally, we demonstrated that HC crossed, in a dose-dependent manner, the corneal barrier when the eyes were topically treated with HC formulations (dose range 0.003-0.33%). No trace of HC was detected in the aqueous humor after ocular administration of eye drops containing the lowest dose of the drug (0.001%), indicating that, at this very low concentration, the drug did not pass the corneal barrier avoiding potential side effects such as intraocular pressure rise. Altogether, these data suggest that HC, at very low concentrations, has an important anti-inflammatory effect both in vitro and in vivo dry eye paradigms and a good safety profile.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Altered ocular surface immune cell profile in patients with dry eye disease
    Nair, Archana Padmanabhan
    D'Souza, Sharon
    Shetty, Rohit
    Ahuja, Prerna
    Kundu, Gairik
    Khamar, Pooja
    Dadachanji, Zelda
    Paritekar, Prajakta
    Patel, Pavitra
    Dickman, Mor M.
    Nuijts, Rudy Mma
    Mohan, Rajiv R.
    Ghosh, Arkasubhra
    Sethu, Swaminathan
    OCULAR SURFACE, 2021, 21 : 96 - 106
  • [2] Dry eye and ocular surface disease
    Yiu, Samuel C.
    SAUDI JOURNAL OF OPHTHALMOLOGY, 2014, 28 (03) : 163 - 163
  • [3] Ocular mucins in dry eye disease
    Portal, Celine
    Gouyer, Valerie
    Gottrand, Frederic
    Desseyn, Jean-Luc
    EXPERIMENTAL EYE RESEARCH, 2019, 186
  • [4] Diagnostic profile of tear osmolarity and inter-ocular variability for dry eye disease
    Wang, Michael T. M.
    Ormonde, Susan E.
    Muntz, Alex
    Craig, Jennifer P.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 48 (02): : 255 - 257
  • [5] Adverse Effect Profile of Topical Ocular Administration of Fingolimod for Treatment of Dry Eye Disease
    Xiao, Weibao
    Sun, Li
    Zhang, Nan
    Ye, Wen
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 120 (04) : 398 - 406
  • [6] Ocular Pain in Patients with Dry Eye Disease
    Sun, Zhongmou
    Satitpitakul, Vannarut
    Kheirkhah, Ahmad
    Crnej, Alja
    Hamrah, Pedram
    Dana, Reza
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [7] Ocular microbiome changes in dry eye disease
    Kamdougha, H.
    Taminiau, B.
    Ben Amor, S.
    Daube, G.
    Menif, B.
    CLINICA CHIMICA ACTA, 2024, 558 : 50 - 50
  • [8] Ocular Surface and Dry Eye in Graves' Disease
    Gurdal, Canan
    Sarac, Ozge
    Genc, Ipek
    Kirimlioglu, Hale
    Takmaz, Tamer
    Can, Izzet
    CURRENT EYE RESEARCH, 2011, 36 (01) : 8 - 13
  • [9] New Pharmacological Treatments for Dry Eye Disease
    Novack G.D.
    Current Ophthalmology Reports, 2013, 1 (2) : 75 - 79
  • [10] In situ metabolic profile and spatial distribution of ocular tissues: New insights into dry eye disease
    Chen, Xiaoniao
    Zhang, Chuyue
    Tian, Lei
    Wu, Lingling
    Jie, Ying
    Wang, Ningli
    Liu, Ran
    Wang, Liqiang
    OCULAR SURFACE, 2022, 24 : 51 - 63